Registered title, quoted from ClinicalTrials.gov
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Zhongshan Hospital, Fudan University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06468280, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 79 years; sex: all
Registered eligibility fields
Pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (Siewert II or III only) with known PD-L1 expression status.
Inclusion criterion 2
Prior PD-1/PD-L1/PD-L2 or other T-cell-targeting therapy.
Exclusion criterion 10
ECOG score ≤2, no surgical contraindications.
Inclusion criterion 6
History of previous malignancies or concurrent other malignancies, with the exception of completely resected basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, and other tumors with no recurrence for at least 5 years.
Exclusion criterion 5
HBsAg-positive with HBV DNA ≥500 IU/mL.
Exclusion criterion 18
Positive HIV antibody.
Exclusion criterion 19
Fertile women with a negative urine or serum pregnancy test and agreement to use effective contraception during the study and for 180 days after the last dose. Non-sterilized men must also agree to use effective contraception.
Inclusion criterion 10
Pregnancy, lactation, or planning for pregnancy.
Exclusion criterion 17
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06468280, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Men or women aged 18-79.
- Pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (Siewert II or III only) with known PD-L1 expression status.
- Gastric cancer with proficient mismatch repair (pMMR) or microsatellite stability (MSS) as determined by immunohistochemistry or NCI-recommended microsatellite markers.
- Primary gastric cancer lesions are resectable, with limited distant metastases meeting the either of the following criteria: (1) condition (a) only; (2) any single condition from (b), with or without (a).
(a) Non-regional intra-abdominal lymph node metastasis: Include metastasis to the superior mesenteric artery, middle colic artery, and para-aortic/retroperitoneal nodes (according to AJCC 8th edition standards).
(b1) Localized peritoneal metastasis: P0CY1, P1a, or P1b, according to the Japanese Classification of Gastric Carcinoma (15th edition).
(b2) Liver metastasis: Up to 5 metastatic lesions. (b3) Lung metastasis: Up to 5 unilateral metastatic lesions. (b4) Ovarian metastasis: Unilateral or bilateral. (b5) Adrenal metastasis: Unilateral or bilateral. (b6) Single-region extra-abdominal lymph node metastasis: Such as cervical, supraclavicular, or mediastinal lymph nodes.
(b7) Bone metastasis limited to a single radiation field. (b8) Other limited metastases as determined by the research team.
- No previous anti-tumor treatments.
- ECOG score ≤2, no surgical contraindications.
- Life expectancy ≥ 3 months.
- Physical condition and organ function suitable for major abdominal surgery.
- Willingness and ability to comply with the study protocol.
- Fertile women with a negative urine or serum pregnancy test and agreement to use effective contraception during the study and for 180 days after the last dose. Non-sterilized men must also agree to use effective contraception.
- Signed informed consent with an understanding that patients can withdraw anytime.
Exclusion Criteria:
- Inability to tolerate oral chemotherapy.
- Primary gastric lesion confined to the mucosa or submucosa with isolated ovarian metastasis.
- Central nervous system metastasis and/or carcinomatous meningitis.
- Allergy to any components of the study medication.
- History of previous malignancies or concurrent other malignancies, with the exception of completely resected basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, and other tumors with no recurrence for at least 5 years.
- Uncontrolled pleural effusion, pericardial effusion, or ascites.
- Weight loss ≥20% within two months before enrollment.
- Upper gastrointestinal obstruction or physiological dysfunction.
- Previous cytotoxic chemotherapy, radiotherapy, immunotherapy, or curative surgery.
- Prior PD-1/PD-L1/PD-L2 or other T-cell-targeting therapy.
- Systemic steroid or immunosuppressant use within 14 days before enrollment.
- Live vaccine within four weeks prior to enrollment.
- Uncontrolled systemic disease.
- Active or past autoimmune diseases that may recur.
- Severe chronic infections or active infections requiring systemic antibacterial, antifungal, or antiviral treatment.
- History of lung disease.
- Pregnancy, lactation, or planning for pregnancy.
- HBsAg-positive with HBV DNA ≥500 IU/mL.
- Positive HIV antibody.
- Conditions that may impact study compliance or participation.
Quoted from ClinicalTrials.gov, NCT06468280, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06468280, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.